Management and treatment outcomes of MDR-TB: Results froma setting with high rates of drug resistance

International Journal of Tuberculosis and Lung Disease

Volumn 19, Issue 9, 2015, Pages 1109-1114

  Ahmad, N ^a   Javaid, A ^b   Basit, A ^b   Afridi, A K ^b   Khan, M A ^c   Ahmad, I ^d   Sulaiman, S A S ^a   Khan, A H ^a  

^a SCHOOL OF PHARMACEUTICAL SCIENCES   (Malaysia)

^b Postgraduate Medical Institute   (Pakistan)

^c PESHAWAR MEDICAL COLLEGE   (Pakistan)

^d QUAID I AZAM UNIVERSITY   (Pakistan)

Author keywords

Comorbidity; Lung cavitations; Ofloxacin; Pyrazinamide; Regimen modification

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; CAPREOMYCIN; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; OFLOXACIN; PYRAZINAMIDE; PYRIDOXINE; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ADD ON THERAPY; ADULT; AGE; ARTICLE; BODY WEIGHT; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DEATH; DRUG TREATMENT FAILURE; EARLY DIAGNOSIS; EARLY INTERVENTION; FEMALE; FOLLOW UP; HUMAN; LUNG CAVITATION; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANT TUBERCULOSIS; MULTIVARIATE ANALYSIS; OBSERVATIONAL STUDY; PAKISTAN; PATIENT CARE; PRIORITY JOURNAL; THORAX RADIOGRAPHY; TREATMENT OUTCOME; ADOLESCENT; DRUG ADMINISTRATION; MIDDLE AGED; MULTIDRUG RESISTANCE; TREATMENT FAILURE; TUBERCULOSIS, MULTIDRUG-RESISTANT; YOUNG ADULT;

ADOLESCENT; ADULT; ANTITUBERCULAR AGENTS; COHORT STUDIES; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OFLOXACIN; PAKISTAN; PYRAZINAMIDE; TREATMENT FAILURE; TUBERCULOSIS, MULTIDRUG-RESISTANT; YOUNG ADULT;

EID: 84973423589     PISSN: 10273719     EISSN: 18157920     Source Type: Journal    
DOI: 10.5588/ijtld.15.0167     Document Type: Article

References (32)

1. Mitnick C D, Castro K G, Harrington M, Sacks LV, Burman W. Randomized trials to optimize treatment of multidrug-resistant tuberculosis. PLOS MED 2007; 4: E292.
2. Caminero J. Treatment of multidrug-resistant tuberculosis: Evidence and controversies. Int J Tuberc Lung Dis 2006; 10: 829-837.
3. Diel R, Vandeputte J, de Vries G, Stillo J, Wanlin M, Nienhaus A. Costs of tuberculosis disease in the European Union: A systematic analysis and cost calculation. Eur Respir J 2014; 43: 554-565.
4. Nathanson E, Gupta R, Huamani P, et al. Adverse events in the treatment of multidrug-resistant tuberculosis: Results from the DOTS-Plus initiative. Int J Tuberc Lung Dis 2004; 8: 1382-1384.
5. Abubakar I, Zignol M, Falzon D, et al. Drug-resistant tuberculosis: Time for visionary political leadership. Lancet Infect Dis 2013; 13: 529-539.
6. Nathanson E, Nunn P, Uplekar M, et al. MDR tuberculosis-critical steps for prevention and control. N Engl J Med 2010; 363: 1050-1058.
7. Wells WA, Ge C F, Patel N, Oh T, Gardiner E, Kimerling M E. Size and usage patterns of private TB drug markets in the high burden countries. PLOS ONE 2011; 6: E18964.
8. World Health Organization. Global tuberculosis report, 2014. WHO/HTM/TB/2014.08. Geneva, Switzerland: WHO, 2014.
9. National TB Control Programme. National guidelines for programmatic management of drug-resistant tuberculosis (PMDT) 2012. Islamabad, Pakistan: NTP, 2012. http://www.ntp.gov.pk/departmentDetail.php?did=18 Accessed May 2015.
10. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. WHO/HTM/TB/2011.6. Geneva, Switzerland: WHO, 2011.
11. Rodriguez M, Monedero I, Caminero J, et al. Successful management of multidrug-resistant tuberculosis under programme conditions in the Dominican Republic. Int J Tuberc Lung Dis 2013; 17: 520-525.
12. World Health Organization. The Global Plan to Stop TB2011-2015: Transforming the fight towards elimination of tuberculosis. WHO/HTM/STB/2010.2. Geneva, Switzerland: WHO, 2010.
13. Falzon D, Mirzayev F, Wares F, et al. Multidrug-resistant tuberculosis around the world: What progress has been made? Eur Respir J 2015; 45: 150-160.
14. Shin S S, Pasechnikov A D, Gelmanova I Y, et al. Treatment outcomes in an integrated civilian and prison MDR-TB treatment program in Russia. Int J Tuberc Lung Dis 2006; 10: 402-408.
15. Batyrshina Y, Petrenko T. Effectiveness of national standardized and WHO regimens and risk factors of unfavorable outcomes in treatment of patients with MDR-TB in Novosibirsk Oblast, Russian Federation. Eur Respir J 2014; 44: 2615.
16. Orenstein E W, Basu S, Shah N S, et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis 2009; 9: 153-161.
17. Johnston J C, Shahidi N C, Sadatsafavi M, Fitzgerald J M. Treatment outcomes of multidrug-resistant tuberculosis: A systematic review and meta-analysis. PLOS ONE 2009; 4: E6914.
18. Nathanson E, Lambregts-van Weezenbeek C, Rich M L, et al. Multidrug-resistant tuberculosis management in resourcelimited settings. Emerg Infect Dis 2006; 12: 1389-1397.
19. Tang S, Tan S, Yao L, et al. Risk factors for poor treatment outcomes in patients with MDR-TB and XDR-TB in China: Retrospective multi-center investigation. PLOS ONE 2013; 8: E82943.
20. Cox H S, Kalon S, Allamuratova S, et al. Multidrug-resistant tuberculosis treatment outcomes in Karakalpakstan, Uzbekistan: Treatment complexity and XDR-TB among treatment failures. PLOS ONE 2007; 2: E1126.
21. Mitnick C D, Franke MF, Rich ML, et al. Aggressive regimens for multidrug-resistant tuberculosis decrease all-cause mortality. PLOS ONE 2013; 8: E58664.
22. Franke M F, Appleton S C, Bayona J, et al. Risk factors and mortality associated with default from multidrug-resistant tuberculosis treatment. Clin Infect Dis 2008; 46: 1844-1851.
23. Kurbatova E V, Taylor A, Gammino V M, et al. Predictors of poor outcomes among patients treated for multidrug-resistant tuberculosis at DOTS-plus projects. Tuberculosis 2012; 92: 397-403.
24. Falzon D, Gandhi N, Migliori G B, et al. Resistance to fluoroquinolones and second-line injectable drugs: impact on MDR-TB outcomes. Eur Respir J 2013; 42: 156-168.
25. Leimane V, Riekstina V, Holtz T H, et al. Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: A retrospective cohort study. Lancet 2005; 365: 318-326.
26. Kliiman K, Altraja A. Predictors of poor treatment outcome in multi-and extensively drug-resistant pulmonary TB. Eur Respir J 2009; 33: 1085-1094.
27. Jabeen K, Shakoor S, Chishti S, Ayaz A, Hasan R. Fluoroquinolone-resistant Mycobacterium tuberculosis, Pakistan, 2005-2009. Emerg Infect Dis 2011; 17: 566.
28. Basit A, Ahmad N, Khan A H, et al. Predictors of two months culture conversion in multidrug-resistant tuberculosis: findings from a retrospective cohort study. PLOS ONE 2014; 9: E93206.
29. Yew W W, Chan C K, Chau C H, et al. Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin-containing regimens. Chest 2000; 117: 744-751.
30. Masjedi MR, Tabarsi P, Chitsaz E, et al., Outcome of treatment of MDR-TB patients with standardised regimens, Iran, 2002-2006. Int J Tuberc Lung Dis 2008; 12: 750-755.
31. Bloss E, Kloksa L, Holt T H, et al. Adverse events related to multidrug-resistant tuberculosis treatment, Latvia, 2000-2004. Int J Tuberc Lung Dis 2010; 14: 275-281.
32. Kang Y A, Kim S Y, Jo K-W, et al. Impact of diabetes on treatment outcomes and long-term survival in multidrugresistant tuberculosis. Respiration 2012; 86: 472-478.